Kezar Life Sciences (NASDAQ:KZR – Get Free Report) released its earnings results on Monday. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.20, Zacks reports.
Kezar Life Sciences Stock Performance
Shares of Kezar Life Sciences stock remained flat at $7.29 on Wednesday. 616,000 shares of the stock were exchanged, compared to its average volume of 125,152. The firm’s 50 day simple moving average is $7.13 and its 200 day simple moving average is $6.57. Kezar Life Sciences has a 12 month low of $3.53 and a 12 month high of $7.55. The stock has a market cap of $53.87 million, a price-to-earnings ratio of -1.18 and a beta of 0.40.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kezar Life Sciences in a research report on Friday. Four analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $6.00.
Hedge Funds Weigh In On Kezar Life Sciences
Institutional investors have recently added to or reduced their stakes in the stock. Landscape Capital Management L.L.C. acquired a new position in Kezar Life Sciences during the 3rd quarter worth approximately $51,000. State Street Corp increased its position in Kezar Life Sciences by 28.4% in the 4th quarter. State Street Corp now owns 27,093 shares of the company’s stock valued at $170,000 after acquiring an additional 6,000 shares during the period. Geode Capital Management LLC raised its stake in shares of Kezar Life Sciences by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 68,167 shares of the company’s stock valued at $429,000 after acquiring an additional 2,665 shares during the last quarter. Aldebaran Capital LLC bought a new position in shares of Kezar Life Sciences during the fourth quarter valued at $507,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Kezar Life Sciences during the fourth quarter valued at $1,741,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.
Kezar Life Sciences Company Profile
Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.
The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.
Featured Articles
- Five stocks we like better than Kezar Life Sciences
- Plug Power Flips The Switch On Profitability
- 3 Sectors That Look Most Vulnerable Ahead of May 15
- Qualcomm Stock Doubles: New Era? Or Another False Start?
- 3 Industrial Stocks That Just Crushed Earnings
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
